Jennifer Krusemark-Millin, DO
Family Medicine · Canton, OHNPI 1215952262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $926 and has fallen 52.1% since, to $444 in 2025.
Across 173 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$759
- AstraZeneca$476
- AbbVie$359
- Amarin Pharma, Inc.$336
- GSK$328
- Pfizer$280
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,82499%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 19 | $759 |
| AstraZeneca | 8 | $476 |
| AbbVie(2 entities) | 23 | $359 |
| Amarin Pharma, Inc. | 18 | $336 |
| GSK | 19 | $328 |
| Pfizer | 17 | $280 |
| Phathom Pharmaceuticals, Inc. | 8 | $173 |
| Lilly USA, LLC | 8 | $161 |
| Inspire Medical Systems, Inc. | 1 | $146 |
| Esperion Therapeutics, Inc. | 1 | $99 |
| Merck | 6 | $93 |
| Dynavax Technologies Corporation | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $63 |
| Novo Nordisk | 3 | $52 |
| Lundbeck LLC | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Amgen | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Exact Sciences | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Vivus LLC | 1 | $20 |
| Currax Pharmaceuticals LLC | 2 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Novartis | 1 | $13 |
| Bausch Health US, LLC | 1 | $12 |
| Sumitomo Pharma America, Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,853 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 129 | $120,418 |
| EliquisApixaban | 111 | $84,315 |
| XareltoRivaroxaban | 99 | $77,672 |
| JardianceEmpagliflozin | 44 | $51,549 |
| MounjaroTirzepatide | 31 | $38,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $33,305 |
| RybelsusSemaglutide | 24 | $31,844 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $30,437 |
| TrulicityDulaglutide | 16 | $20,884 |
| JanuviaSitagliptin Phosphate | 25 | $19,755 |
| VraylarCariprazine Hcl | 12 | $17,053 |
| OzempicSemaglutide | 17 | $16,558 |
| Repatha SureclickEvolocumab | 16 | $12,988 |
| GemtesaVibegron | 26 | $12,309 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $11,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Nexium | $476 | $123,470140 claims |
| PfizerEliquis | $280 | $84,315111 claims |
| Johnson & JohnsonXarelto | $759 | $77,67299 claims |
| Lilly USA, LLCMounjaro, Trulicity | $161 | $59,76247 claims |
| Novo NordiskRybelsus, Ozempic | $52 | $48,40241 claims |
| GSKTrelegy Ellipta | $328 | $33,30551 claims |
| MerckJanuvia | $93 | $19,75525 claims |
| AbbVieVraylar | $359 | $17,05312 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $9 | $12,30926 claims |
| NovartisEntresto | $13 | $7,35218 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $7,04230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Canton
- Irwin LilenfieldCanton$29K
- Diana BrewsterCanton$19K
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.